Clinical Study Results
What serious adverse reactions happened during the study?
There were 6.3% of participants who had serious adverse reactions during the
study. This was 2 out of 32 participants.
The serious adverse reactions that happened during the study were:
• Diarrhea. This happened in 1 participant in Part A who got 20 mg/kg of durvalumab
and 1 mg/kg of tremelimumab.
• Increase in amount of aspartate aminotransferase in the body, which is a sign of liver
damage. This happened in 1 participant in Part B who got 20 mg/kg of durvalumab
and 3 mg/kg of AZD9150.
None of the participants died due to serious adverse reactions during the study.
What adverse reactions happened during the study?
The most common adverse reaction during the study was:
• Increase in amount of alanine aminotransferase in the body, which is a sign of liver
damage.
The table below shows the adverse reactions that happened in at least 3
participants during the study. There were other adverse reactions, but those
happened in fewer participants.
9